SCHEMBL13313867

SCHEMBL13313867

COCCOCCNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GNPAT O15228 1/20 0.40
▸ CAPN1 P07384 5/20 0.39
▸ PSMB11 A5LHX3 2/20 0.39
▸ PSMD11 O00231 2/20 0.39
▸ PSMD12 O00232 2/20 0.39
▸ PSMD14 O00487 2/20 0.39
▸ PSMA7 O14818 2/20 0.39
▸ PSMD3 O43242 2/20 0.39
▸ PSMC3 P17980 2/20 0.39
▸ PSMB1 P20618 2/20 0.39
▸ PSMA1 P25786 2/20 0.39
▸ PSMA2 P25787 2/20 0.39
▸ PSMA3 P25788 2/20 0.39
▸ PSMA4 P25789 2/20 0.39
▸ PSMB8 P28062 2/20 0.39
▸ PSMB9 P28065 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13625026 1.00 SYK (0.42) SYKALDH1A1MEN1KMT2AGNPAT
SCHEMBL13313868 1.00 SYK (0.42) SYKALDH1A1MEN1KMT2AGNPAT
SCHEMBL13313886 1.00 SYK (0.42) SYKALDH1A1MEN1KMT2AGNPAT
SCHEMBL14014083 0.89 ALDH1A1 (0.42) SYKALDH1A1MEN1KMT2AGNPAT
SCHEMBL13157948 0.88 GNPAT (0.41) SYKMEN1KMT2AGNPATCA12
SCHEMBL13313862 0.88 SYK (0.49) SYKCAPN1MMP8
SCHEMBL13038592 0.88 SYK (0.49) SYKCAPN1MMP8
SCHEMBL13010184 0.86 MEN1 (0.42) SYKMEN1KMT2AGNPATCA12
SCHEMBL13625031 0.85 CTSB (0.42) SYKALDH1A1MEN1KMT2AGNPAT
SCHEMBL13625027 0.85 CTSB (0.42) SYKALDH1A1MEN1KMT2AGNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides UNIVERSITY OF SOUTH FLORIDA (US) 2010-06-03 — — US disclosed
US-7618944-B2 Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-17 — — US disclosed
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides IAPP, APP, TTR SYK 1417/4885ALDH1A1 4414/4885MEN1 271/4885
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES IAPP, APP, TTR SYK 2774/4885ALDH1A1 4688/4885MEN1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback